• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Orexo - Articles and news items

Mundipharma obtains global ex-US rights to Zubsolv

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

Orexo’s Zubsolv (buprenorphine and naloxone sublingual tablet) is a potential new treatment option for patients with opioid dependence…

24-week clinical study strengthens the evidence of the therapeutic value of Zubsolv for maintenance treatment of opioid dependence

Industry news / 22 April 2015 / Victoria White

Orexo has announced data from a trial assessing the long-term safety and efficacy of Zubsolv sublingual tablet for the treatment of opioid dependence…